New cocktail aims to knock out prostate cancer spread
NCT ID NCT04267887
First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 3 times
Summary
This phase 2 trial tests whether adding apalutamide, abiraterone, and prednisone after chemotherapy can better control metastatic prostate cancer that still responds to hormone therapy. Seven men with high-risk, untreated disease are receiving this combination. The main goal is to see if prostate-specific antigen (PSA) levels drop to very low levels, indicating a strong response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- apalutamide, abiraterone acetate, prednisone, and androgen deprivation therapy
- What this could lead to
- If successful, this combination could offer a more effective way to control advanced prostate cancer and delay its progression.
- What could go wrong
- This is a very small early-phase trial with only 7 participants, so results may not apply broadly. The drugs can cause side effects like fatigue, high blood pressure, and liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-SENSITIVE PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- Blood test could tell doctors when to stop prostate cancer treatment early
- Could a stronger first dose of targeted radiation beat back advanced prostate cancer?
- Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread